Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semorinemab in moderate Alzheimer's Disease
NCT03828747Phase 2Completed
- Sponsor
- Genentech
- Start
- Jan 2019
- Primary completion
- Jul 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Semorinemab with Placebo (2 arms). Primary endpoints: Alzheimer's Disease Assessment Scale-Cognitive Subscale (11-Item) at Week 61 and Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory at Week 61. Started Jan 2019; status: completed.
02
Drugs
semorinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03828747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03828747.